Activity of bis-carbamoyloxymethyl derivatives of pyrroles and pyrrolizines against human tumor xenografts in nude mice.
The activities of the pyrrolizines, Compounds I and II, and the pyrroles, Compounds IV and V, are reported in nude mouse-grown HT-29 human adenocarcinoma of the colon, DO 1 human oat carcinoma of the lung, and CL 1 human duct cell carcinoma of the breast (coded as CX-1, LX-1, and MX-1, respectively, by the National Cancer Institute). Compounds II and IV were active against all three experimental tumors; both compounds produced significant tumor regression in the human breast tumor xenograft and Compound IV caused tumor regression in the human lung tumor xenograft.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002460:Cell Line; D003110:Colonic Neoplasms / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011758:Pyrroles / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*; D014183:Transplantation, Heterologous
D011758:Pyrroles; D011759:Pyrrolidines